ICI Therapy Toxicities In Psoriasis

    September 2023 in “ Journal of the American Academy of Dermatology ”
    Haig Pakhchanian, Rahul Raiker, Erisa Alia, Mairead R. Baker, Min Deng
    TLDR ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
    This study analyzed the toxicity profile of immune checkpoint inhibitor (ICI) therapy in patients with psoriasis using data from over 100 million patients. Two cohorts of 1,151 patients each, with and without a history of psoriasis, were compared. The study found that patients with psoriasis who received ICI therapy had higher odds of developing gastrointestinal toxicity (adjusted hazard ratio [aHR] 1.5) and endocrine toxicity (aHR 1.33) within one year of treatment initiation.
    Discuss this study in the Community →